As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
17 Analysts have issued a Amicus Therapeutics, Inc. forecast:
17 Analysts have issued a Amicus Therapeutics, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 599 599 |
21%
21%
|
|
| Gross Profit | 537 537 |
21%
21%
|
|
| EBITDA | 42 42 |
82%
82%
|
|
| EBIT (Operating Income) EBIT | 35 35 |
140%
140%
|
|
| Net Profit | -14 -14 |
87%
87%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
| Head office | United States |
| CEO | Bradley Campbell |
| Employees | 499 |
| Founded | 2002 |
| Website | www.amicusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


